DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

The K-Hotel Seoul

2024 年 09 月 25 日 9:00 上午 - 2024 年 09 月 25 日 6:00 下午

70, Baumoe-ro 12-gil,, Seocho-gu,, Seoul 06769, Korea, Republic of

DIA Asia Meeting 2024 (Sep.25, 2024)

Accelerating Drug Development with Advanced Innovation for Asian Patients

概览

This Asia meeting 2024 will bring together industry, regulatory authorities, and academia to address pressing challenges in public health and drug development in Asia. The event will feature sessions where speakers will discuss recent advancements in regulatory science and the use of innovative tools to expedite clinical development and pharmacovigilance (PV).
One key topic will focus on regulatory agencies’ perspectives, highlighting recent advances in regulatory science and how the medical and regulatory landscapes are evolving. Speakers will also explore areas ripe for innovation in regulatory science.
Another topic will delve into the impact of real-world data (RWD) on regulatory decision-making, featuring case studies showcasing RWD’s role in indication expansion, new drug approvals, and post-marketing studies. Speakers will assess data quality, integration, analysis methods, and practical considerations.
Additionally, experts from the pharmaceutical industry will discuss the latest developments and practical applications of AI in clinical development. Topics will include indication selection, patient enrichment, AI-supported diagnosis, operational excellence, and AI-powered medical writing.
Lastly, This event will explore the integration of AI technologies in safety surveillance, signal detection, and risk management in pharmaceuticals. Attendees will gain insights into leveraging AI for enhanced patient safety outcomes through collaboration and knowledge-sharing.

View Program

精选主题

Session 1: Recent Advances in Regulatory Science in Asia

Session 2: Regulatory Update and Real-examples in Regulatory Approval in RWD

Session 3: How to Leverage AI to Accelerate Clinical Development

Session 4: AI-Powered Pharmacovigilance: Ensuring Patient Well-being

Featured

Want to learn more about DIA Asia Meeting 2024 (Sep.25, 2024)? You've come to the right site!

项目委员会

  • Yil-Seob  Lee, MD, PhD
    Yil-Seob Lee, MD, PhD Professor, Dept of Clinical Pharmacology
    CHA Global clinical research center, CHA University, Korea, Republic of
  • Hironobu  Saito, PhD
    Hironobu Saito, PhD Specially Appointed Professor
    Tottori University, Chromosome Egineering Research Center, Japan
  • Xiaojun (Wendy)  Yan, MD, MBA
    Xiaojun (Wendy) Yan, MD, MBA Senior Vice President, Senior Advisor
    BeiGene (Beijing) Co., Ltd., China
  • Jing Ping  Yeo, PhD
    Jing Ping Yeo, PhD Global Head, Project Operations & Head, Transformation
    George Clinical, Singapore
  • Xiaoyuan  Chen, PhD
    Xiaoyuan Chen, PhD Director, GCP Officer
    Beijing Tsinghua Changgung Hospital, China
  • Youngju  Choi, PhD
    Youngju Choi, PhD Director General
    National Institute of Food & Drug Safety (NIFDS), Korea, Republic of
  • Fengyun (Vicky)  Han
    Fengyun (Vicky) Han Senior Director, Head of Regulatory Policy for Asia Pacific
    Johnson & Johnson Pte. Ltd., Singapore
  • Qiang  Li
    Qiang Li
    Servier (Beijing) Pharmaceutical R&D co.ltd, China
  • MinJung  Lim, MPharm
    MinJung Lim, MPharm Managing director
    MediSafe, Pharmacovigilance Services, Korea, Republic of
  • Jessica  Liu, MD
    Jessica Liu, MD VP, Head of Merges and Acquisition Management Department
    Tigermed Consulting Co., Ltd, China
  • Atsushi  Ogawa
    Atsushi Ogawa
    ICON Japan K.K., Japan
  • In-sook  Park
    In-sook Park Director General
    Korean Regulatory Science Center, Korea, Republic of
  • Hyouyoung  Rhim, MD, MSc
    Hyouyoung Rhim, MD, MSc Vice President
    Yuhan Pharm inc., Korea, Republic of
  • Juyoung  Shin, PharmD, MPH
    Juyoung Shin, PharmD, MPH Professor
    College of Pharmacy, Sungkyunkwan University, Korea, Republic of
  • Shun  Jin, MBA
    Shun Jin, MBA Head, Regulatory Affairs, APMA
    Sandoz Asia Pacific Pharmaceutical Pte., Ltd., Singapore
  • Danny  Soon
    Danny Soon Chief Executive Officer, CRIS, Executive Director, SCRI, Interim Executive
    Director, ACTRIS, Singapore
  • Yuji  Kumagai, MD, PhD
    Yuji Kumagai, MD, PhD Professor, Kitasato Clinical Research Center
    Kitasato University Hospital, Japan
  • Yoshiaki  Uyama, PhD, RPh
    Yoshiaki Uyama, PhD, RPh Associate Executive Director
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Jun (Catherine)  Xie
    Jun (Catherine) Xie Sr. Manager of Safety Assessment
    Pfizer (China) Research and Development Co., Ltd., China
  • Kum Cheun  Wong, PharmD
    Kum Cheun Wong, PharmD Head Asia Pacific Regulatory & Development Policy
    Novartis Asia Pacific Pharmaceuticals Pte. Ltd., Singapore
  • Shogo  Nakamori, MBA, MSc, RPh
    Shogo Nakamori, MBA, MSc, RPh Senior Vice President & Managing Director, DIA Japan, Korea, and Singapore
    DIA, Japan
  • Young Joo  Park
    Young Joo Park VP, Korea, Singapore, and Southeast Asia
    DIA, Korea, Republic of

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。